Phase 3
Completed N=18
Statin Therapy in the Treatment of Sepsis
Source: ClinicalTrials.gov NCT00676897 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcomePrimary: Time to Shock Reversal — 44.4; 28.6 hours
◆ Published Evidence
Established
62citations · ~4 / year
Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shock.
Summary
Simvastatin will attenutat IL-6 levels and lead to a more rapid shock reversal than placebo
Linked Publications (3)
-
Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shock.
-
Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis.
-
Statins role in the prevention and treatment of sepsis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Shock Reversal |
44.4; 28.6 | — |
| SECONDARY Inflammatory Marker Levels |
-98; 269; -370; -423; -0.52; -2.17 | — |
Eligibility Criteria
Inclusion Criteria
- Greater than 18 years old
- Hypotensive requiring vasopressors
- Suspected Infection
Exclusion Criteria
- Pregnant
- Liver Failure (ALT or AST > 120)
- Rhabomyolysis (CPK > 3x normal)
- Comfort care measures status
- Chronic Liver Disease (Cirrhosis)
- Use of Cyclosporin, Digoxin, Statins
- Patients who are unable to take medications by mouth or NGT
Data sourced from ClinicalTrials.gov (NCT00676897) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.